PT91583A - Verfahren zur herstellung von immunsupprimierenden pharmazeutischen zusammensetzungen die transglutaminasen enthalten - Google Patents

Verfahren zur herstellung von immunsupprimierenden pharmazeutischen zusammensetzungen die transglutaminasen enthalten

Info

Publication number
PT91583A
PT91583A PT91583A PT9158389A PT91583A PT 91583 A PT91583 A PT 91583A PT 91583 A PT91583 A PT 91583A PT 9158389 A PT9158389 A PT 9158389A PT 91583 A PT91583 A PT 91583A
Authority
PT
Portugal
Prior art keywords
transglutaminasen
immunsupprimierenden
enthalten
die
zur herstellung
Prior art date
Application number
PT91583A
Other languages
English (en)
Other versions
PT91583B (pt
Inventor
Thomas Stief
Norbert Heimburger
Hans Ulrich Schorlemmer
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of PT91583A publication Critical patent/PT91583A/pt
Publication of PT91583B publication Critical patent/PT91583B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
PT91583A 1988-08-31 1989-08-30 Processo para a preparacao de composicoes farmaceuticas imunossupressoras contendo transglutaminases PT91583B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3829524A DE3829524A1 (de) 1988-08-31 1988-08-31 Verwendung von transglutaminasen als immunsuppressiva

Publications (2)

Publication Number Publication Date
PT91583A true PT91583A (pt) 1990-03-30
PT91583B PT91583B (pt) 1995-05-31

Family

ID=6361974

Family Applications (1)

Application Number Title Priority Date Filing Date
PT91583A PT91583B (pt) 1988-08-31 1989-08-30 Processo para a preparacao de composicoes farmaceuticas imunossupressoras contendo transglutaminases

Country Status (11)

Country Link
US (2) US5464615A (pt)
EP (1) EP0358995B1 (pt)
JP (1) JP2831045B2 (pt)
KR (1) KR0154523B1 (pt)
AT (1) ATE94762T1 (pt)
AU (1) AU627489B2 (pt)
CA (1) CA1338776C (pt)
DE (2) DE3829524A1 (pt)
DK (1) DK174512B1 (pt)
ES (1) ES2059658T3 (pt)
PT (1) PT91583B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829523A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva
JPH03240738A (ja) * 1990-02-20 1991-10-28 Hoechst Japan Ltd 糖尿病性壊疽治療剤
EP0598133B1 (en) * 1992-04-21 2000-03-29 Ajinomoto Co., Inc. Remedy for wound
DE69326349T2 (de) * 1992-11-12 2000-03-02 Mayberg, Marc R. Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen
DE69431430T2 (de) * 1993-03-30 2003-05-22 Hoechst Japan Ltd., Tokio/Tokyo Faktor XIII zur Behandlung von Hautwunden
DE19630557C2 (de) * 1996-07-18 1998-07-02 Schuppan Detlef Priv Doz Dr Dr Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Gewebe-Transglutaminase (tTG) sowie die Verwendung von tTG in Diagnose und Therapie
AU7483798A (en) * 1997-05-14 1998-12-08 Zymogenetics Inc. Use of factor xiii for the manufacture of a medicament for the treatment of reperfusion injury and mucosal damage
EP1201136A1 (en) * 2000-10-31 2002-05-02 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Food grade transglutaminase inhibitor and uses thereof
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP2392258B1 (en) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-informatics system
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
WO2010129819A2 (en) 2009-05-06 2010-11-11 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2017009136A1 (en) 2015-07-15 2017-01-19 Novo Nordisk Health Care Ag Factor xiii for the treatment of interstitial cystitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT359652B (de) * 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
EP0086627B1 (en) * 1982-02-12 1985-08-28 Unitika Ltd. Anti-cancer device
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
JPS63196520A (ja) * 1987-02-09 1988-08-15 Hoechst Japan Kk 潰瘍性大腸炎治療剤
ES2060646T3 (es) * 1987-02-09 1994-12-01 Lubrizol Genetics Inc Virus rna hibrido.
US5013719A (en) * 1988-05-13 1991-05-07 Merrell Dow Pharmaceuticals Inc. Method of effecting immunosuppression
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva

Also Published As

Publication number Publication date
DE3829524A1 (de) 1990-03-01
AU4090489A (en) 1990-03-08
AU627489B2 (en) 1992-08-27
ES2059658T3 (es) 1994-11-16
CA1338776C (en) 1996-12-10
EP0358995A3 (en) 1990-08-16
DK174512B1 (da) 2003-05-05
ATE94762T1 (de) 1993-10-15
DK427989A (da) 1990-03-01
EP0358995A2 (de) 1990-03-21
JP2831045B2 (ja) 1998-12-02
JPH02108631A (ja) 1990-04-20
EP0358995B1 (de) 1993-09-22
DE58905671D1 (de) 1993-10-28
KR0154523B1 (ko) 1998-11-16
US5464615A (en) 1995-11-07
US5695753A (en) 1997-12-09
PT91583B (pt) 1995-05-31
KR900002802A (ko) 1990-03-23
DK427989D0 (da) 1989-08-30

Similar Documents

Publication Publication Date Title
PT91583A (pt) Verfahren zur herstellung von immunsupprimierenden pharmazeutischen zusammensetzungen die transglutaminasen enthalten
GR3023289T3 (en) Analgesic agent and its use
ATE42206T1 (de) Verfahren und zusammensetzung zur gleichzeitigen reinigung und desinfektion von kontaktlinsen.
DE68903206D1 (de) N-(mercaptoalkyl)-omega-hydroxyalkylamide und ihre verwendung als reduktionsmittel in einem verfahren zur bleibenden gestaltung von haaren.
ATE36457T1 (de) Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
DE3680271D1 (de) Thrombolytische zusammensetzung und verfahren zu deren herstellung.
DE3869230D1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
DE68927030D1 (de) Verfahren zur Konservierung ophthalmischer Lösungen und Zusammensetzungen dafür
ATE97576T1 (de) Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression.
ATE181549T1 (de) Verfahren zur herstellung von (s)-3-amino-1- substituiert-pirrolidine
ATE142689T1 (de) Verfahren zur herstellung von aktiviertem protein c
DE59511030D1 (de) Verfahren und Teilreagenz zur Bestimmung von Eisen in Serum
DE3678621D1 (de) Verfahren und testzusammensetzung zur bestimmung von wasserstoffperoxyd.
FR2635008B1 (fr) Agent activateur de la productivite specifique des cellules animales recombinantes a base de polyvinylpyrrolidone et milieu de culture defini le contenant
ATE147390T1 (de) Verfahren zur herstellung von 3',4'- anhydrovinblastin
DE68917376D1 (de) Verfahren zur Herstellung eines Antistatischen Mittels und Methacrylharz-Zusammensetzung.
GR3020389T3 (en) Calibrator and use thereof in an immuno-assay
ATE93832T1 (de) Verfahren zur herstellung von 4,6-dimethyl-7hydroxynonan-3-on.
FI101475B1 (fi) Menetelmä kudosplasminogeeniaktivaattorijohdannaisen valmistamiseksi
ES2000764A6 (es) Procedimiento para el desencalado de pieles
ATA342887A (de) Verfahren und einrichtung zur verkohlung von biomassen in zwei fluidisierungsstufen
ATE85365T1 (de) Verfahren zur bestimmung von protein c-inhibitor.
ES2066733A1 (es) Complejo consistente en un activador del plasminogeno y albumina de suero y procedimiento para prepararlo.
ATE52538T1 (de) Verfahren zur herstellung von diperoxidodecandionsaeure enthaltenden agglomeraten und die verwendung derselben in bleichmitteln.
ATE54673T1 (de) Mittel zur entschwefelung von geschmolzenem eisen sowie verfahren zur herstellung des mittels.

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19941118

PC3A Transfer or assignment

Free format text: 980126 CENTEON PHARMA GMBH DE

PD3A Change of proprietorship

Owner name: AVENTIS BEHRING GMBH

Effective date: 20000316

PD3A Change of proprietorship

Free format text: ZLB BEHRING GMBH DE

Effective date: 20041018

PD4A Change of proprietorship

Owner name: CSL BEHRING GMBH, DE

Effective date: 20070807

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20091118